Rep. Kean Jr. Absence Raises Questions
Rep. Tom Kean Jr. has been absent from Congress since March 5, missing 50 votes while still trading stocks.
Objective Facts
Rep. Tom Kean Jr. has been absent from Congress since March 5, missing 50 votes. Financial records reviewed by NOTUS indicate Kean bought and sold shares of eight different stocks between March 10 and March 31, with combined value from $50,008 to $190,000. Kean's team said the absence is due to unspecified health issues, and representatives Chris Smith and Jeff Van Drew have tried to call and text him to no avail, with Van Drew telling Politico it has been "radio silence." House Speaker Mike Johnson said he spoke to Kean by phone and that he is attending to a personal health matter and expects to be back to 100% very soon. As House Speaker Mike Johnson navigates a narrow majority, a Republican member's prolonged absence could impact the ability to move must-pass legislation and Johnson can only afford to lose two votes on any party-line bill.
Left-Leaning Perspective
Left-leaning outlets have focused on the mysteriously prolonged absence and the implications of continued stock trading during Kean's disappearance. The DCCC amplified NOTUS reporter Dave Levinthal's investigative reporting showing Kean made stock trades worth $50,008 to $190,000 between March 10 and March 31 while absent from Congress. Daily Kos columnist Mark Sumner questioned why Kean's social media and congressional office maintained activity during the absence, suggesting "radio silence" from a major New Jersey political family was unusual and suspicious. The New Republic emphasized the timing as particularly damaging to Kean given the district's competitive dynamics and Trump administration decisions unpopular in the district, like opening an ICE detention facility there. Left-leaning coverage argues the absence undermines Kean's credibility just as he faces reelection in a toss-up district. Democratic activists launched a "Where is Tom?" grassroots campaign questioning his availability. Raw Story emphasized Kean's past violations of the STOCK Act with late trade disclosures in 2023, noting he has not co-sponsored the Stop Insider Trading Act despite running as an ethics reformer. Left outlets stressed the contradiction between Kean's 2022 campaign attacking opponent Tom Malinowski for undisclosed stock trades and his current continued trading during health-related absence. Left-leaning coverage largely omits the full context of Kean's health privacy and the sympathetic concern expressed by some colleagues, instead emphasizing the stock trading angle and the opacity of his absence as a broader accountability and governance issue.
Right-Leaning Perspective
Right-leaning outlets have expressed frustration that GOP leadership did not handle the situation more proactively and transparently. RedState columnist Jennifer Oo argued that "the New Jersey GOP and Speaker Johnson are projecting weakness on this matter, by not knowing why Kean was absent and when he plans to return." She criticized the delay in communicating about Kean's status, writing that had media outlets not publicized the absence, "this may have remained a mystery and something Democrats could twist to their advantage." Right-leaning sources, through Republican National Committee member and Kean campaign attorney Bill Palatucci, have sought to normalize the absence as a routine health matter that voters will forgive. Palatucci told Politico that "everyone understands from their own family experiences that people run into unexpected health issues" and predicted it would be "long forgotten come the fall." Union County GOP Chair Carlos Santos conveyed to Politico that he had been texting with Kean and was "told he'll be fine," offering reassurance without specifics. Right-leaning coverage emphasizes the slim Republican majority's vulnerability and Kean's seat's competitiveness but largely frames the situation as manageable if handled properly. Some conservative outlets note the timing is politically unfortunate but stress that extended absences are not unprecedented and that media focus may be overblown given privacy considerations.
Deep Dive
Rep. Tom Kean Jr.'s month-long absence from Congress and continued stock trading reveal tensions between legislative accountability, medical privacy, and political positioning. Kean won his seat in 2022 by attacking predecessor Tom Malinowski over undisclosed stock trades, making ethics a centerpiece of his campaign. Yet Kean promised but failed to implement a true blind trust for his assets, and NOTUS's April 2025 investigation documented how he backed away from that 2023 commitment, citing cumbersome ethics rules. His continued personal trading since March—even while absent from Congress—creates an optics problem regardless of whether it was legally permissible or personally directed, especially given his prior STOCK Act violations with late trade disclosures in 2023. Both sides correctly identify the core political problem: Kean represents New Jersey's 7th District, rated a toss-up by Cook Political Report, and Democrats have already targeted it as a top pickup opportunity. His absence strengthens their argument that he is unavailable to constituents. The slim Republican majority compounds this—Johnson can afford to lose only two votes on party-line bills. Kean's month-long disappearance without explanation forced Speaker Johnson to personally call him before any statement was issued, and his office still has not disclosed the nature of his health issue or expected return date. Left outlets criticize this lack of transparency; right outlets criticize GOP leadership for appearing weak. Both observations have merit: Kean arguably owes constituents more information about his capacity to serve, while GOP leadership arguably should have controlled the narrative earlier rather than allowing a media-driven story to develop. What remains unresolved is whether the absence reflects a serious, ongoing health condition that may affect Kean's ability to campaign and serve, or a temporary issue that will resolve before the June 2 primary and November election. The timeline matters: if Kean returns healthy and energized within weeks, the absence becomes a footnote; if it extends through the primary or reflects a chronic condition, it becomes a legitimate question about his fitness to run. The continued stock trading while absent, even if legally compliant, will persist as ammunition for Democratic opponents arguing he is out of touch and unavailable. For Republicans, Kean's seat is among their most vulnerable, and the absence has only weakened his standing in an already difficult race.